American Journal of Pathology
Oct 09, 2018
Notizia
FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi. As Tegsedi is approved,...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
